Table 3. AEs and treatment-related AEs (n=20).
| AE, n [%] | Apatinib TEAE, n [%] | Chemotherapy TEAE, n [%] | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All grade | Grade 3–4 | Grade 5 | All grade | Grade 3–4 | Grade 5 | All grade | Grade 3–4 | Grade 5 | |||
| Any grade AE | 20 [100] | 17 [85] | 4 [20] | 17 [85] | 12 [60] | 1 [5] | 18 [90] | 11 [55] | 0 | ||
| Decreased neutrophil count | 16 [80] | 6 [30] | 0 | 6 [30] | 2 [10] | 0 | 16 [80] | 6 [30] | 0 | ||
| Decreased leukocyte count | 15 [75] | 6 [30] | 0 | 7 [35] | 3 [15] | 0 | 14 [70] | 5 [25] | 0 | ||
| Anemia | 14 [70] | 4 [20] | 0 | 4 [20] | 2 [10] | 0 | 5 [25] | 2 [10] | 0 | ||
| Hypoalbuminemia | 11 [55] | 0 | 0 | 1 [5] | 0 | 0 | 0 | 0 | 0 | ||
| Hypertension | 10 [50] | 6 [30] | 0 | 7 [35] | 3 [15] | 0 | 2 [10] | 1 [5] | 0 | ||
| Fatigue | 10 [50] | 3 [15] | 0 | 8 [40] | 3 [15] | 0 | 8 [40] | 3 [15] | 0 | ||
| Hypokalemia | 9 [45] | 3 [15] | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Increased γ-glutamyltransferase | 8 [40] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 4 [20] | 1 [5] | 0 | ||
| Loss of appetite | 8 [40] | 0 | 0 | 5 [25] | 0 | 0 | 6 [30] | 0 | 0 | ||
| Increased aspartate aminotransferase | 8 [40] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 4 [20] | 1 [5] | 0 | ||
| Increased lactate dehydrogenase | 8 [40] | 0 | 0 | 2 [10] | 0 | 0 | 5 [25] | 0 | 0 | ||
| Decreased platelet count | 7 [35] | 2 [10] | 0 | 1 [5] | 0 | 0 | 4 [20] | 1 [5] | 0 | ||
| Increased alanine aminotransferase | 6 [30] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 5 [25] | 1 [5] | 0 | ||
| Proteinuria | 6 [30] | 0 | 0 | 5 [25] | 0 | 0 | 2 [10] | 0 | 0 | ||
| Diarrhea | 6 [30] | 0 | 0 | 4 [20] | 0 | 0 | 3 [15] | 0 | 0 | ||
| Increased alkaline phosphatase | 6 [30] | 1 [5] | 0 | 3 [15] | 0 | 0 | 4 [20] | 0 | 0 | ||
| Hypocalcemia | 5 [25] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Abdominal pain | 5 [25] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Oral mucositis | 5 [25] | 2 [10] | 0 | 3 [15] | 1 [5] | 0 | 3 [15] | 1 [5] | 0 | ||
| Constipation | 4 [20] | 0 | 0 | 0 | 0 | 0 | 1 [5] | 0 | 0 | ||
| Asthenia | 4 [20] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | ||
| Vomiting | 4 [20] | 0 | 0 | 2 [10] | 0 | 0 | 3 [15] | 0 | 0 | ||
| Increased blood bilirubin | 4 [20] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | ||
| Hypophosphatemia | 3 [15] | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Dysphonia | 3 [15] | 0 | 0 | 3 [15] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Abdominal distention | 3 [15] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cough | 3 [15] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Prolonged clotting time | 3 [15] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Decreased blood urea | 3 [15] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Palmar-Plantar Erythrodysesthesia Syndrome | 3 [15] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 2 [10] | 0 | 0 | ||
| Increased carcinoembryonic antigen | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Hypoproteinemia | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Hyponatremia | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Nausea | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Pulmonary infection | 2 [10] | 0 | 1 [5] | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Pneumonia | 2 [10] | 0 | 1 [5] | 1 [5] | 0 | 1 [5] | 0 | 0 | 0 | ||
| Hypercholesterolemia | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Myalgia | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Mouth ulcers | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 2 [10] | 0 | 0 | ||
| Epigastric discomfort | 2 [10] | 0 | 0 | 0 | 0 | 0 | 1 [5] | 0 | 0 | ||
| Insomnia | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Pain | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Weight loss | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Peripheral nerve injury | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Dizziness | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Increased blood uric acid | 2 [10] | 0 | 0 | 0 | 0 | 0 | 2 [10] | 0 | 0 | ||
| Hematuria | 2 [10] | 0 | 0 | 1 [5] | 0 | 0 | 1 [5] | 0 | 0 | ||
| Increased blood fibrinogen | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Hypercoagulable state | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Limb pain | 2 [10] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | 2 [10] | 1 [5] | 0 | ||
| Increased tumor markers | 2 [10] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Incomplete intestinal obstruction | 1 [5] | 0 | 1[5] | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Abdominal infection | 1 [5] | 1 [5] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Inflammation of anus | 1 [5] | 1 [5] | 0 | 1 [5] | 1 [5] | 0 | 0 | 0 | 0 | ||
| Hyperglycemia | 1 [5] | 1 [5] | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Bone marrow failure | 1 [5] | 1 [5] | 0 | 1 [5] | 1 [5] | 0 | 1 [5] | 1 [5] | 0 | ||
| Oral pain | 1 [5] | 1 [5] | 0 | 1 [5] | 1 [5] | 0 | 0 | 0 | 0 | ||
| Disease progression | 1 [5] | 0 | 1[5] | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Drug hypersensitivity | 1 [5] | 1 [5] | 0 | 0 | 0 | 0 | 1 [5] | 1 [5] | 0 | ||
AE, adverse events; TEAE, treatment emergent adverse events.